S
Sorin Rugină
Researcher at Ovidius University
Publications - 55
Citations - 2105
Sorin Rugină is an academic researcher from Ovidius University. The author has contributed to research in topics: Internal medicine & Population. The author has an hindex of 12, co-authored 48 publications receiving 1963 citations.
Papers
More filters
Journal ArticleDOI
HLA-B*5701 Screening for Hypersensitivity to Abacavir
Simon Mallal,Elizabeth J. Phillips,Giampiero Carosi,Jean-Michel Molina,Cassy Workman,Janez Tomazic,Eva Jägel-Guedes,Sorin Rugină,Oleg Kozyrev,Juan Flores Cid,Phillip Hay,David Nolan,Sara Hughes,Arlene R Hughes,Susanna Ryan,Nicholas Fitch,D. Thorborn,Alastair Benbow +17 more
TL;DR: HLA-B*5701 screening reduced the risk of hypersensitivity reaction to abacavir and showed that a pharmacogenetic test can be used to prevent a specific toxic effect of a drug.
Journal ArticleDOI
Eltrombopag Increases Platelet Numbers in Thrombocytopenic Patients With HCV Infection and Cirrhosis, Allowing for Effective Antiviral Therapy
Nezam H. Afdhal,Geoffrey Dusheiko,Edoardo G. Giannini,Pei-Jer Chen,Kwang Hyub Han,Aftab Mohsin,Maribel Rodriguez-Torres,Sorin Rugină,Igor G. Bakulin,E.J. Lawitz,Mitchell L. Shiffman,Ghias Un Nabi Tayyab,Fred Poordad,Yasser Mostafa Kamel,Andres Brainsky,James Geib,Sandra Y. Vasey,Rita Patwardhan,Fiona Campbell,Dickens Theodore +19 more
TL;DR: Eltrombopag increases platelet numbers in thrombocytopenic patients with HCV and advanced fibrosis and cirrhosis, allowing otherwise ineligible or marginal patients to begin and maintain antiviral therapy, leading to significantly increased rates of SVR.
Journal ArticleDOI
Forty‐eight‐week efficacy and safety and early CNS tolerability of doravirine (MK‐1439), a novel NNRTI, with TDF/FTC in ART‐naive HIV‐positive patients
Josep M. Gatell,Javier O Morales-Ramirez,Debbie Hagins,Melanie A. Thompson,Arasteh Keikawus,Christian Hoffmann,Sorin Rugină,Olayemi Osiyemi,Simona Escoriu,Robin Dretler,Charlotte M. Harvey,Xia Xu,Hedy Teppler +12 more
TL;DR: Doravirine plus open‐label tenofovir/emtricitabine (TDF/FTC) demonstrated potent antiretroviral activity comparable to EFV 600 mg qhs plus TDF/ FTC and was generally well tolerated at week 24.
Journal ArticleDOI
Pharmacokinetics, safety and efficacy of darunavir/ritonavir in treatment-experienced children and adolescents.
Stéphane Blanche,Rosa Bologna,Pedro Cahn,Sorin Rugină,Patricia M. Flynn,Claudia Fortuny,Peter Vis,Vanitha Sekar,Ben van Baelen,Inge Dierynck,Sabrina Spinosa-Guzman +10 more
TL;DR: In treatment-experienced children and adolescents, DRV/r showed comparable exposure to adults with appropriate dose selection, favorable safety and tolerability, improved body weight and significant virologic response.
Journal ArticleDOI
Lipid profiles for etravirine versus efavirenz in treatment-naive patients in the randomized, double-blind SENSE trial.
Gerd Fätkenheuer,Claudine Duvivier,Armin Rieger,J. Durant,David Rey,W. Schmidt,Andrew Hill,Y van Delft,Stephan Marks,N. Vetter,R. Greil,Court Pedersen,M. Storgaard,Philippe Morlat,Christine Katlama,L. Cotte,C. Duvvier,Stefan Esser,C. Stellbrink,M. Stoll,Christoph Stephan,Albrecht Stoehr,Juergen K. Rockstroh,Dénes Bánhegyi,L. Itzchak,E. Shahar,S. Maayan,Dan Turner,Adriano Lazzarin,Andrea Antinori,G. Carosi,Lorenzo Minoli,G. Di Perri,Gaetano Filice,M. Andreoni,D. Duiculescu,Sorin Rugină,S. Erscoiu,A. Streinu,A. Pronin,Vadim Pokrovsky,B. Gruzdev,A. Yakovlev,E. Voronin,B Clotet,Gatell Jm,Jose R. Arribas,Daniel Podzamczer,Pere Domingo,C. Miralles Alvarez,J. Hernandez Quero,Hansjakob Furrer,J. Feher,Margaret A. Johnson,Julie Fox,Mark T. Nelson,M Fisher,Chloe Orkin +57 more
TL;DR: In the SENSE trial, first-line treatment with 400 mg of etravirine once daily plus two nucleoside analogues led to fewer grade 3 or 4 lipid elevations compared with efavirenz plus three nucleosid analogues.